Kaempferol 3-O-sophoroside

Kaempferol 3-O-sophoroside is an orally active derivative of Kaempferol. It exhibits anti-inflammatory, analgesic, and antidepressant effects. Kaempferol 3-O-sophoroside is an inhibitor of the cell surface receptor toll-like receptor (TLR) 2/4 for High mobility group box 1 (HMGB1), and it also exerts anti-inflammatory effects by blocking the activation of NF-κB expression and the production of TNF-α. Kaempferol 3-O-sophoroside promotes the production of brain-derived neurotrophic factor (BDNF) and enhances autophagy by binding to AMP-activated protein kinase (AMPK), thereby exerting antidepressant effects. Kaempferol 3-O-sophoroside holds promise for research in the fields of inflammation and neurodegenerative diseases^[1][2][3][4]. IC50 & Target:Kaempferol 3-O-sophoroside possesses barrier integrity activity, inhibitory activity on cell adhesion and migration to endothelial cells by blocking the activation of NF-κB expression and production of TNF-α, thereby endorsing its usefulness as therapy for vascular inflammatory diseases^[1]. In Vitro:Kaempferol 3-O-sophoroside (5 μM, 48 h) does not affect the cell viability of human umbilical vein endothelial cells (HUVECs)^[1].
Kaempferol 3-O-sophoroside (0-5 μM, 3 h) dose-dependently reduces barrier disruption in lipopolysaccharide (HY-D1056)-stimulated human umbilical vein endothelial cells (HUVECs), while it does not alter the integrity of the cell barrier when used alone^[1].
Kaempferol 3-O-sophoroside (0-5 μM, 24 h) inhibits neutrophil adhesion to lipopolysaccharide (HY-D1056)-stimulated human umbilical vein endothelial cells (HUVECs) and suppresses neutrophil migration to HUVECs by blocking the activation of NF-κB and the production of TNF-α^[1].
In Vivo:Kaempferol 3-O-sophoroside (10 and 20 mg/kg, p.o., once daily for 20 days) binds to AMP-activated protein kinase (AMPK) to promote brain-derived neurotrophic factor (BDNF) production and autophagy enhancement in corticosterone (HY-B1618)-induced mouse depression model and chronic unpredictable mild stress (CUMS) model, ultimately achieving antidepressant effects^[3].
Kaempferol 3-O-sophoroside (100 and 200 mg/kg, p.o., 30-minute administration duration) exhibits analgesic effects in the acetic acid-induced writhing mice model^[4].